Genomic and Proteomic Network for Premature Birth Resea*

早产研究的基因组和蛋白质组网络*

• 批准号: 7354086
• 负责人: MICHAEL W. VARNER
• 金额: $ 78.01万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-02-01 至 2011-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7354086
• 关键词: Accounting; Arts; Caring; Child; Class; Clinical; Clinical Research; Clinical Trials; Clinics and Hospitals; Communities; Community Hospitals; Enrollment; Genes; Genetic; Genetic Polymorphism; Genomics; Health Sciences; Healthcare Systems; International; Medical Genetics; Medicine; Multicenter Trials; National Institute of Child Health and Human Development; Patients; Population; Premature Birth; Productivity; Proteomics; Publishing; Reporting; Research; Research Design; Research Infrastructure; Sampling Studies; Techniques; Universities; Utah; Woman; cDNA Arrays; cytokine; experience; fetal; myometrium; reproductive; stillbirth; tertiary care

This proposal constitutesthe University of Utah application for the NICHD Genomic and Proteomic Network for PrematureBirth Research. The University of Utah has numerousunique strengths that make it an ideal center for the network. These include: I. Research Productivity in Multicenter Collaborative Studies: The University of Utah Maternal-Fetal Medicine (MFM) Division has made substantial contributions to over 15 multicenter clinical trials during the past five years and is a leading recruitment center for the NICHD/MFMU Network. Over 12,000 Utah patients were enrolled in the recently completed FASTER trial, accounting for almost 32% of subjects in the 12- center trial. The University of Utah also participates in the Stillbirth Collaborative Research Network and the Global Network for Women's and Children'sHealth Research. II. Premature Birth: The Universityof Utah enjoys international recognitionas a center of excellence for clinical care and research on premature birth. III.Expertise in the Use of Genomic and Proteomic Techniques to Study Premature Birth: The Maternal-Fetal Medicine Divisionhas published on the use of cDNA microarray to identify genes with labor-specific expression within myometrium and has also reported on cytokine polymorphisms and spontaneous preterm birth in various ethnic populations. We have also recently reported experience with the use of proteomics to identify potentialpredictors of term and preterm birth. IV. Reproductive and Medical Genetics: Utah's distinctpopulation has attracted numerousworld-class geneticists to the University. State of the art molecularand clinical genetic capabilities will be made availableto the Network. V. University / Community Synergy: MFM specialistsin Utah have a unique clinical and research partnership that crosses competing health care systems and affords universalaccess to patients for clinical research. VI. Proven Enrollment Strategy: Research infrastructure is currentlyin place at four regional tertiary care centers that has and will continue to allow the University of Utah to be among the leading recruitment centers for large multicenter trials.

该提案构成了犹他大学对 NICHD 基因组和蛋白质组学的申请 早产研究网络。犹他大学拥有众多独特的优势 使其成为理想的网络中心。其中包括： I. 多中心的研究生产力 合作研究：犹他大学母胎医学 (MFM) 部门做出了 在过去五年中对超过 15 项多中心临床试验做出了重大贡献，是 NICHD/MFMU 网络的领先招聘中心。超过 12,000 名犹他州患者接受了 参加最近完成的 FASTER 试验，占 12-12 期受试者的近 32% 中心审判。犹他大学还参加了死产合作研究网络 以及全球妇女和儿童健康研究网络。 二.早产：犹他大学作为早产中心享有国际认可 卓越的早产临床护理和研究。 III. 基因组学应用专业知识 研究早产的蛋白质组学技术：母胎医学部门 发表了关于使用 cDNA 微阵列来识别具有劳动力特异性表达的基因 子宫肌层，还报道了细胞因子多态性和自发性早产 各民族人口。我们最近还报告了使用蛋白质组学的经验 确定足月和早产的潜在预测因素。四．生殖和医学遗传学： 犹他州独特的人口吸引了众多世界级的遗传学家来到该大学。状态 先进的分子和临床遗传能力将提供给网络。五、 大学/社区协同：犹他州的 MFM 专家拥有独特的临床和研究 跨越竞争性医疗保健系统的伙伴关系，为患者提供普遍服务 临床研究。六．行之有效的招生策略：研究基础设施目前已到位 四个区域三级护理中心已经并将继续允许犹他大学 是大型多中心试验的领先招募中心之一。